ArticleDrug and alcohol review2026
Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community-Recruited Study.
Article in Drug and alcohol review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionGabapentin is widely prescribed off-label to treat pain. However, there are concerns about the proliferation of medical and non-medical use, and the potential increased risk of overdose death associated with concurrent opioid use. Despite these considerations, prescription gabapentin use among people who use unregulated drugs is uncharacterised in Canada. Therefore, we investigated trends and factors associated with being prescribed gabapentin for pain among community-recruited people who use opioids.
methodsData were derived from three prospective cohort studies of people who use unregulated drugs in Vancouver, Canada, restricted to periods of opioid use (i.e., unregulated use, non-medical use, and/or opioid agonist treatment). We characterised factors associated with reporting gabapentin for pain between 2014 and 2020 using multivariable generalised estimating equations. Trends in self-reported prescription (2014-2020) and non-medical (2016-2024) gabapentin use were explored.
resultsBetween 2014 and 2020, we included 10,999 observations from 2039 participants who had a baseline median age of 38 years and were 62.4% male and 57.5% White. Gabapentin prescriptions for pain were reported by 255 (12.5%) participants. Observations reporting a neuropathic pain diagnosis had 3.54 times the adjusted odds (95% CI 2.81, 4.46) of being prescribed gabapentin. From 2014 to 2020, the prevalence of gabapentin prescriptions rose from 5.4% to 7.8%. Non-medical gabapentin use remained low. DISCUSSION AND
conclusionsAmong people who use opioids, we observed an increase in gabapentin prescriptions for pain between 2014 and 2020. Gabapentin prescriptions were strongly associated with reporting a neuropathic pain diagnosis. Rates of non-medical gabapentin use were substantially lower than rates reported internationally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.